The Bioeconomy ​​Information Sharing and Analysis Center (BIO-ISAC) has released an advisory following an investigation into an advanced persistent threat (APT) attack targeting biomanufacturing facilities.

Researchers at biomedical and cybersecurity company BioBright began investigating the APT attack after a large, unnamed biomanufacturing facility was involved in a cyberattack in the spring of this year. BIO-ISAC said BioBright identified a malware loader “that demonstrated a high degree of autonomy as well as metamorphic capabilities”.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The APT attack, now named Tardigrade, was also discovered at a second unidentified biomanufacturing site in October.

In the threat advisory, published this week, BIO-ISAC advised biomanufacturing sites and their partners to assume they are targets of the malware and “take necessary steps to review their cybersecurity and response postures”.

Analysis of the cyberattack is ongoing, but BIO-ISAC said it had decided to bring its initial findings to the public’s attention due to the “advanced characteristics and continued spread” of the active APT.

The pharmaceutical industry has been a prime target for cybercriminals for some time, and the development of valuable new Covid-19 vaccines and drugs has only heightened the risk of a security breach for drug companies.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Last November, the National Cyber Security Centre (NCSC) reported that it had defended the UK health sector from 723 incidents between September 2019 and August 2020, with around 200 of the attacks relating to Covid-19.

This year, the number of cybersecurity incidents managed by the NCSC reached an unprecedented 777. The centre said around 20% of the organisations it had supported were related to vaccines and the health sector.

Pharmaceutical Technology Excellence Awards - Nominations Closed

Nominations are now closed for the Pharmaceutical Technology Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
Awarded the 2025 Pharmaceutical Technology Excellence Award for Business Expansion in Integrated Manufacturing, Upperton Pharma Solutions is rapidly expanding its UK GMP and sterile manufacturing footprint. Find out how Upperton’s integrated CDMO model helps pharma companies move from early development to clinical and niche commercial supply with fewer handovers and faster timelines.

Discover the Impact